heat shock protein family D (Hsp60) member 1Genealiases: CPN60 · GROEL · HLD4 · HSP-60 · HSP60 · HSP65
Q-omics provides the consensus-scored HSPD1 profile across patient tissues and cancer cell-line models. HSPD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HSPD1 is differentially expressed in 18, with the highest sampling consensus in COAD. Additionally, HSPD1 protein abundance shows 25,104 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, COAD, and LSCC as cancer lineages where HSPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPD1 survival associations across molecular data types. HSPD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPD1 RNA expression–survival associations across cancer types. High HSPD1 expression shows unfavorable associations in LUAD, LIHC, KIRP, ACC, ESCA and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HSPD1 RNA expression.
This table summarizes HSPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HSPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPD1 shows higher tumor expression in COAD, LUAD, BLCA, HNSC, STAD and LUSC. The COAD box plot shows higher HSPD1 RNA expression in tumor versus normal tissue (log2 FC = +1.488, t-test p < 0.001).
This table shows molecular features associated with HSPD1 in patient tissues and cancer cell lines. In patient samples, HSPD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
